Dostarlimab-gxly Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dostarlimab-gxly Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
110
Registered trials
119
Result records
3
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Dostarlimab-gxly can convert its Monoclonal antibody profile and PD-1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dostarlimab-gxly (query alias: dostarlimab) |
|---|---|
| Modality / target | Monoclonal antibody; PD-1; PD-1 inhibitors |
| Highest global status | Approved |
| Originator | AnaptysBio, Inc. |
| Active developers | Tesaro, Inc., GSK Plc, GlaxoSmithKline Trading Services Ltd. |
The MCP disease footprint includes Advanced Endometrial Carcinoma, Recurrent Endometrial Cancer, MSI-H/dMMR Solid Tumors. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07652515 | Phase 4 | Not yet recruiting | 100 | Number of participants with Grade 3 or greater treatment-emergent adverse events (TEAEs) up to Week 49 |
| NCT07381777 | Phase 2 | Not yet recruiting | 270 | Clinical complete response (cCR) at 12 months |
| NCT07336147 | Phase 2 | Recruiting | 45 | Dostarlimab, with radiotherapy in sandwich sequence for small cell neuroendocrine cervical carcinoma. PFS at 2 years (from 57% to 75%) PFS is defined the date of starting chemotherapy with dostarlimab to the date of progression defined with RECIST 1.1 |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
Phase 2/3; n=758; evaluation: not stated. Reported fields: OS(Median) = 11.9 Months (95% Confidence Interval, 10.6 - 14.2); OS(Median) = 11.3 Months (95% Confidence Interval, 9.5 - 13.9); OS(Median): Hazard Ratio (HR) = 0.85(95% CI, 0.68 - 1.06), P-Value = 0.079708
Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: PFS(4-year) = 15.7 % ( 7.2 - 27.0); PFS(4-year) = 57.9 % ( 42.3 - 70.6)
Organ preservation strategy using dostarlimab for dMMR/MSI-H resectable solid tumors with whole-genome–based MRD monitoring (D-CURE: EPOC2401).
Phase 2; n=80; evaluation: Positive. Reported fields: CCR(12-month) = 56.0 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dostarlimab-gxly addresses Advanced Endometrial Carcinoma, Recurrent Endometrial Cancer, MSI-H/dMMR Solid Tumors. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-10-25 | AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard | Approved | US$250.0M upfront; US$50.0M milestones |
| 2019-01-22 | GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company | Approved | US$5,100.0M stated total |
| 2014-03-13 | TESARO and AnaptysBio Announce Collaboration and Exclusive Worldwide License Agreement for Multiple Immuno-Oncology Programs | Preclinical | US$17.0M upfront; US$540.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination therapies using CDK4 inhibitors with PD-1 axis binding antagonists”. The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with PD1/PD-l1 inhibitors”. The milestone feed surfaced a patent-application signal described as “Resiquimod in combination with a PD-1 or PD-l1 antagonist for treating cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
